Clinical Trials Logo

Cognitive Dysfunction clinical trials

View clinical trials related to Cognitive Dysfunction.

Filter by:

NCT ID: NCT04263519 Withdrawn - Alzheimer Disease Clinical Trials

A Pilot Open Labeled Study of Tacrolimus in Alzheimer's Disease.

Start date: December 1, 2021
Phase: Phase 2
Study type: Interventional

A Pilot open labeled study of Tacrolimus in Alzheimer's Disease.

NCT ID: NCT04106869 Withdrawn - Clinical trials for Cognitive Dysfunction

The Influence of Ventilation on Perioperative Neurocognitive Disorders

Start date: November 1, 2019
Phase: N/A
Study type: Interventional

This prospective study is designed to examine the influence of intra-operative ventilation on perioperative neurocognitive disorders in patients undergoing total hip arthroplasty.

NCT ID: NCT04064021 Withdrawn - Alzheimer Disease Clinical Trials

Acupuncture Treatment for Improving Alzheimer's Dementia

Start date: January 1, 2025
Phase: N/A
Study type: Interventional

Evaluate cognitive improvement pre amd post acupuncture treatment in patients with probable alzheimer's dementia as measured by MOCA score and also per form A( measure of patient's personal information). Also caregiver input.

NCT ID: NCT04055532 Withdrawn - Clinical trials for Amyotrophic Lateral Sclerosis (ALS)

Biomarkers in Neurodegenerative Diseases

Start date: October 1, 2019
Phase:
Study type: Observational [Patient Registry]

The general purpose of this observational study is to examine biomarkers associated with the pathology of neurodegenerative diseases to potentially develop novel therapeutic approaches.

NCT ID: NCT04051801 Withdrawn - Clinical trials for Cognitive Impairment

Multiple Ascending Dose Putative Cognitive Enhancer VU319

Start date: May 25, 2021
Phase: Phase 1
Study type: Interventional

This is a safety study of the molecule VU319 to ascertain pharmacokinetic and pharmacodynamic data and test cognitive enhancement in healthy volunteers.

NCT ID: NCT04019665 Withdrawn - Alzheimer Disease Clinical Trials

Self-screening of Cognitive Impairment in Primary Care

OCEANE
Start date: May 27, 2020
Phase: N/A
Study type: Interventional

According to 2011 HAS recommendations, early detection of Alzheimer disease is the major objective in order to allow an earlier care and support. These recommendations strengthen general practitioner role, who plays a key role in the identification of cognitively impaired patients. HAS recommendations are the use of MMSE like test (Mini Mental State Examination) at general practitioner office. A self-screening test, without medical presence, would allow a self-administered cognitive assessment by the patient. A review of the literature about self-administered cognitive tests has been realized. The Self-Administered Gerocognitive Examination (SAGE) has been chosen. It is a brief, valid and reliable cognitive assessment tool, rated on 22 points, which allows an early detection of cognitive impairment, with a sensitivity close to the MMSE test. Nevertheless, SAGE has never been tested at home without medical supervision. In this study, the investigators will determine if SAGE scores at home correlates with MMSE scores at general practitioner office. Patients with inclusion criteria will be recruited during the general practitioner consultation and will have a clinical assessment included MMSE and clinical data collection. Then, SAGE will be given to the patient in order to be completed at home without medical supervision and send to the general practitioner.

NCT ID: NCT03947671 Withdrawn - Cardiac Surgery Clinical Trials

Active Temperature Management After Cardiac Surgery and Its Effect on Postoperative Cognitive Dysfunction

Start date: January 22, 2020
Phase: Phase 2
Study type: Interventional

This study will assess the effect of active postoperative temperature management and its effect on the cognitive function in patients following coronary artery bypass graft (CABG) surgery to determine if active postoperative temperature management to maintain normothermia reduces postoperative cognitive dysfunction (POCD) in this population. Additionally, the investigators will explore differences in temperature control variability by using temperature management wraps combined with acetaminophen vs. acetaminophen alone in a pilot arm.

NCT ID: NCT03851198 Withdrawn - Clinical trials for Mild Cognitive Impairment

Early Diagnosis of Patients With Mild Cognitive Impairment Through the Parameterization of Functional Tests.

Start date: April 1, 2020
Phase: N/A
Study type: Interventional

The present study aims to develop an index formed by the variables, functional tests, scales and instruments that best discriminate between healthy subjects and subjects with MCI and that allows the stratification of different levels of severity of MCI, and to validate new systems for the early diagnosis of subjects with mild cognitive impairment.

NCT ID: NCT03773185 Withdrawn - Clinical trials for Mild Cognitive Impairment

A Comparative Study of Brain Structure and Amyloid Load in MCI Patients

Start date: December 15, 2018
Phase:
Study type: Observational [Patient Registry]

Older people with DM are at greater risk of cognitive decline than their counterparts with DM. Cognitive impairment in older people with DM may be associated with non-AD related brain atrophy and white matter disease. The investigators therefore propose to compare DM and non-DM older people with amnesic MCI in brian volumes, white matter disease and amyloid load. 30 older people with aMCI, 30 older people with aMCI and DM, age 65-85 will be recruited. They all will have amyloid PET scan and MRI brain scan.

NCT ID: NCT03585907 Withdrawn - Alzheimer Disease Clinical Trials

Feasibility and Efficacy of Dietary Interventions for Older Adults With Subjective Cognitive Decline

Start date: September 2, 2019
Phase: N/A
Study type: Interventional

This study aims to assess if/how dietary interventions (i.e., the Modified Atkins Diet (MAD) and/or the Mediterranean-Dietary Approaches to Stop Hypertension (DASH) Intervention for Neurodegenerative Delay (MIND)) might prevent, delay onset, alleviate symptoms, or otherwise alter the course of subjective cognitive decline (SCD) likely due to Alzheimer's disease (AD). We hypothesize that participants will tolerate both diets well and that the MAD will result in more favorable changes in cognition and other functioning.